View in EDS HTML Full Text PDF Full Text

The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.

Saved in:
Bibliographic Details
Title: The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.
Authors: Block MS; Mayo Clinic Cancer Center, Rochester, MN, USA., Clubb JHA; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Mäenpää J; Docrates Cancer Center, Helsinki, Finland.; Tampere University, Faculty of Medicine and Medical Technology, Tampere, Finland., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Quixabeira DCA; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Kudling T; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Jirovec E; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Haybout L; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., van der Heijden M; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Zahraoui S; TILT Biotherapeutics Ltd, Helsinki, Finland., Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Raatikainen S; TILT Biotherapeutics Ltd, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Basnet S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Ojala N; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Pellinen T; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland., Hemmes A; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland., Välimäki K; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland., Pasanen A; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Alanko T; Docrates Cancer Center, Helsinki, Finland., Adamo D; Mayo Clinic Cancer Center, Rochester, MN, USA., Ramadan S; Docrates Cancer Center, Helsinki, Finland., Sormunen J; Docrates Cancer Center, Helsinki, Finland., Kononen J; Docrates Cancer Center, Helsinki, Finland., Cohen JW; Merck & Co. Inc., Rahway, NJ, USA., Chisamore MJ; Merck & Co. Inc., Rahway, NJ, USA., Goldfinch J; TILT Biotherapeutics Ltd, Helsinki, Finland., Sorsa S; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Havunen R; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Kistler C; TILT Biotherapeutics Ltd, Helsinki, Finland., Kalervo A; TILT Biotherapeutics Ltd, Helsinki, Finland., Cervera-Carrascon V; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Dos Santos JM; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Hemminki A; TILT Biotherapeutics Ltd, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland. akseli.hemminki@helsinki.fi.
Source: Nature communications [Nat Commun] 2025 Feb 05; Vol. 16 (1), pp. 1381. Date of Electronic Publication: 2025 Feb 05.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39910037
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Block+MS%22">Block MS</searchLink>; Mayo Clinic Cancer Center, Rochester, MN, USA.<br /><searchLink fieldCode="AU" term="%22Clubb+JHA%22">Clubb JHA</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Mäenpää+J%22">Mäenpää J</searchLink>; Docrates Cancer Center, Helsinki, Finland.; Tampere University, Faculty of Medicine and Medical Technology, Tampere, Finland.<br /><searchLink fieldCode="AU" term="%22Pakola+S%22">Pakola S</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Quixabeira+DCA%22">Quixabeira DCA</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Kudling+T%22">Kudling T</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Jirovec+E%22">Jirovec E</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Haybout+L%22">Haybout L</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22van+der+Heijden+M%22">van der Heijden M</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Zahraoui+S%22">Zahraoui S</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Grönberg-Vähä-Koskela+S%22">Grönberg-Vähä-Koskela S</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Raatikainen+S%22">Raatikainen S</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Arias+V%22">Arias V</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Basnet+S%22">Basnet S</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Ojala+N%22">Ojala N</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Pellinen+T%22">Pellinen T</searchLink>; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Hemmes+A%22">Hemmes A</searchLink>; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Välimäki+K%22">Välimäki K</searchLink>; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Pasanen+A%22">Pasanen A</searchLink>; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Alanko+T%22">Alanko T</searchLink>; Docrates Cancer Center, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Adamo+D%22">Adamo D</searchLink>; Mayo Clinic Cancer Center, Rochester, MN, USA.<br /><searchLink fieldCode="AU" term="%22Ramadan+S%22">Ramadan S</searchLink>; Docrates Cancer Center, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Sormunen+J%22">Sormunen J</searchLink>; Docrates Cancer Center, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Kononen+J%22">Kononen J</searchLink>; Docrates Cancer Center, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Cohen+JW%22">Cohen JW</searchLink>; Merck & Co. Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Chisamore+MJ%22">Chisamore MJ</searchLink>; Merck & Co. Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Goldfinch+J%22">Goldfinch J</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Sorsa+S%22">Sorsa S</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Havunen+R%22">Havunen R</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Kistler+C%22">Kistler C</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Kalervo+A%22">Kalervo A</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Cervera-Carrascon+V%22">Cervera-Carrascon V</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Dos+Santos+JM%22">Dos Santos JM</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Hemminki+A%22">Hemminki A</searchLink>; TILT Biotherapeutics Ltd, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland. akseli.hemminki@helsinki.fi.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2025 Feb 05; Vol. 16 (1), pp. 1381. <i>Date of Electronic Publication: </i>2025 Feb 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39910037
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-025-56482-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1381
    Titles:
      – TitleFull: The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Block MS
      – PersonEntity:
          Name:
            NameFull: Clubb JHA
      – PersonEntity:
          Name:
            NameFull: Mäenpää J
      – PersonEntity:
          Name:
            NameFull: Pakola S
      – PersonEntity:
          Name:
            NameFull: Quixabeira DCA
      – PersonEntity:
          Name:
            NameFull: Kudling T
      – PersonEntity:
          Name:
            NameFull: Jirovec E
      – PersonEntity:
          Name:
            NameFull: Haybout L
      – PersonEntity:
          Name:
            NameFull: van der Heijden M
      – PersonEntity:
          Name:
            NameFull: Zahraoui S
      – PersonEntity:
          Name:
            NameFull: Grönberg-Vähä-Koskela S
      – PersonEntity:
          Name:
            NameFull: Raatikainen S
      – PersonEntity:
          Name:
            NameFull: Arias V
      – PersonEntity:
          Name:
            NameFull: Basnet S
      – PersonEntity:
          Name:
            NameFull: Ojala N
      – PersonEntity:
          Name:
            NameFull: Pellinen T
      – PersonEntity:
          Name:
            NameFull: Hemmes A
      – PersonEntity:
          Name:
            NameFull: Välimäki K
      – PersonEntity:
          Name:
            NameFull: Pasanen A
      – PersonEntity:
          Name:
            NameFull: Alanko T
      – PersonEntity:
          Name:
            NameFull: Adamo D
      – PersonEntity:
          Name:
            NameFull: Ramadan S
      – PersonEntity:
          Name:
            NameFull: Sormunen J
      – PersonEntity:
          Name:
            NameFull: Kononen J
      – PersonEntity:
          Name:
            NameFull: Cohen JW
      – PersonEntity:
          Name:
            NameFull: Chisamore MJ
      – PersonEntity:
          Name:
            NameFull: Goldfinch J
      – PersonEntity:
          Name:
            NameFull: Sorsa S
      – PersonEntity:
          Name:
            NameFull: Havunen R
      – PersonEntity:
          Name:
            NameFull: Kistler C
      – PersonEntity:
          Name:
            NameFull: Kalervo A
      – PersonEntity:
          Name:
            NameFull: Cervera-Carrascon V
      – PersonEntity:
          Name:
            NameFull: Dos Santos JM
      – PersonEntity:
          Name:
            NameFull: Hemminki A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 05
              M: 02
              Text: 2025 Feb 05
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1